TY - JOUR
T1 - Monitoring and treatment of minimal residual cancer of the prostate.
AU - Mathé, G.
AU - Schally, A. V.
AU - Comaru-Schally, A. M.
AU - Mauvernay, R. Y.
AU - Vovan, M. L.
AU - Machover, D.
AU - Misset, J. L.
AU - Court, B.
AU - Bouchard, P.
AU - Duchier, J.
PY - 1989/3/1
Y1 - 1989/3/1
N2 - In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimization of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.
AB - In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimization of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024633791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024633791&partnerID=8YFLogxK
M3 - Article
C2 - 2525968
AN - SCOPUS:0024633791
VL - 126
SP - 65
EP - 74
JO - Bulletin de la Societe des Sciences Medicales du Grand-Duche de Luxembourg
JF - Bulletin de la Societe des Sciences Medicales du Grand-Duche de Luxembourg
SN - 0037-9247
IS - 1
ER -